Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature Reviews …, 2018 - go.gale.com
Rheumatoid arthritis (RA) is an inflammatory joint disorder that affects 0.5-1% of the
population worldwide [1, 2]. Despite major advances in our understanding of RA …
population worldwide [1, 2]. Despite major advances in our understanding of RA …
[HTML][HTML] Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature reviews …, 2018 - ncbi.nlm.nih.gov
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature Reviews …, 2018 - search.proquest.com
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature reviews …, 2018 - pubmed.ncbi.nlm.nih.gov
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
[PDF][PDF] Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing, RW Wood… - 2018 - researchgate.net
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature reviews …, 2018 - europepmc.org
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature Reviews …, 2018 - pure.johnshopkins.edu
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
[引用][C] Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature Reviews …, 2018 - cir.nii.ac.jp
Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.
EM Bouta, RD Bell, H Rahimi, L Xing… - Nature reviews …, 2018 - europepmc.org
Although clinical outcomes for patients with rheumatoid arthritis (RA) have greatly improved
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …
with the use of biologic and conventional DMARDs, approximately 40% of patients do not …